|JAK2 Mutation V617F, Quantitative, PCR, Blood [JAK2]|
| WSLH Department:|| Cytogenetics|
|WSLH Test Code:||840C44a|
|Includes:||JAK2 Mutation V617F detection|
|Methodology:||**(CPT Code: 81270)** Real-Time PCR followed by Melting Point Analysis|
|Availability:||Once a week.|
|Turn-around Time:||10 Days|
|Specimen Requirements:||4 mL, (2 mL pediatric)
Lavender top EDTA|
|Collection Kit/Container:|| |
|Patient Preparation:|| |
|Collection Instructions:||For bone marrow specimens, order JAK2 Gene,V617F Mutation, Qualititative (ARUP# 0051245) performed by the ARUP Laboratories.
Contact UWHC Test Referral office at (608)262-6388 prior to collection. Ordering source must fill out the Referral Screening Flow Sheet prior to specimen collection.|
|Specimen Handling and Transport:||Do not centrifuge sample.
Transport specimen to laboratory immediately. Refrigerate specimen if not delivered immediately. Do not freeze sample.|
|Requisition Form:||Cytogenetics Lab Neoplasia Diagnosis Form #132|
|Required Information:|| |
|Results include:||Expected results not detected. A written interpretive report is provided by the laboratory.|
|Limitations:||Analytical measurement range for this test is 2.5 to 99.0% Jak2 V617F allele burden. Detection range is 1.0% allele burden and above.|
|Additional Tests Recommended:|| |
|Additional Comments:||For whole blood samples in which the Jak2 V617F allele is detected and within the analytical measurement range (AMR), a quantitative value for the mutant allele burden will be reported. If the Jak2 V617F allele burden is detected (≥1.0%) but below 2.5%, a result of "Detected" will be reported. If the Jak2 V617F allele is not detected or the result is below the detection range of 1.0%, a result of "Not detected" will be reported.
A result of 'Not detected" does not rule out the presence of the Jak2 V617F allele. False negative results may be due to inhibitory substances that may be present in the specimen. Inadequate specimen collection, processing and storage may invalidate test results. This test should not be used as the only criterion to form a clinical conclusion. Instead, results should be correlated with other test results, patient symptoms and clinical presentation.
The performance characteristics of this test were validated by UWHC Clinical Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The UWHC Clinical Laboratories is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
A written interpretive report is provided by the laboratory.|
|Additional Tests Performed:|| |